

January 30, 2025

National Stock Exchange of India Limited

Exchange Plaza,

Plot No. C/1, G Block,

Bandra Kurla Complex, Bandra (E)

Mumbai - 400 051

BSE Limited

Corporate Relationship Department

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400 001

Symbol: LALPATHLAB Scrip Code: 539524

Sub: <u>Press Release on Un-audited Financial Results (Standalone and Consolidated)</u>
<u>for the Quarter and Nine Months ended December 31, 2024</u>

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2024.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral Company Secretary & Compliance Officer

Encl.: As above



For Immediate Release January 30, 2025

Dr Lal PathLabs Limited records revenue of Rs 597 Cr in Q3 FY 2024-25

New Delhi, India, January 30, 2025 – Dr Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2024.

Consolidated Performance Highlights: Q3 FY25 vs Q3 FY24

- Revenue increased by 10.7% in Q3 FY25
- EBITDA increased by 9.6% with a margin of 25.8%
- PAT increased by 19.3% with a margin for of 16.4%
- Third Interim Dividend of Rs. 6 per share for FY25

Financial Overview (Consolidated) in Rs Cr

Particulars	Q3			YTD		
	FY25	FY24	Gr %	FY25	FY24	Gr %
Revenue	597	539	10.7%	1859	1681	10.6%
Operating Expenditure	443	398	11.1%	1332	1217	9.5%
EBITDA	154	141	9.6%	527	465	13.3%
Margins	25.8%	26.1%		28.3%	27.6%	
Other Income	25	18		68	51	
Depreciation Cost	36	36		106	107	
EBIT	144	123	16.8%	489	408	19.6%
<i>Margins</i>	24.1%	22.8%		<i>26.3%</i>	24.3%	
Finance Cost	5	7		17	23	
PBT	138	116	19.4%	471	386	22.2%
Margins	23.2%	21.5%		<i>25.4%</i>	22.9%	
PAT	98	82	19.3%	337	277	21.8%
Margins	16.4%	15.3%		18.1%	16.4%	
EPS	11.6	9.8	18.7%	39.9	32.9	21.4%

About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr Lal Pathlabs Limited



As on March 31, 2024 the company has 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr Lal PathLabs Limited

+91 124 3016500 cfo@lalpathlabs.com

Kritika Khatwani *Adfactors PR*

+91 8604801332 kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.